C/2026/5425

19.10.2026

**Prior notification of a concentration**

**Case M.12585 – BC PARTNERS / ACS DOBFAR / INFORLIFE**

**Candidate case for simplified procedure**

**(Text with EEA relevance)**

(C/2026/5425)

1. On 9 October 2026, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]).

This notification concerns the following undertakings:

— BC Partners Fund XII (United Kingdom), controlled by BC Partners LLP ('BC Partners', United Kingdom),

— ACS Dobfar S.p.A. ('ACSD', Italy).

BC Partners Fund XII and ACSD will acquire within the meaning of Articles 3(1)(b) and 3(4) of the Merger Regulation joint control of InfoRLife SA ('InfoRLife', Switzerland), a company currently solely controlled by ACSD.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are the following:

— BC Partners Fund XII is an investment fund advised and controlled by BC Partners, an alternative investment manager focused on private equity, credit and real estate investments,

— ACSD is a pharmaceutical company active in the manufacture of active pharmaceutical ingredients as well as finished dose pharmaceuticals in both solid and injectable form.

3. InfoRLife is a Swiss pharmaceutical company currently solely controlled by ACSD that specialises in sterile fill-finish manufacturing of ready-to-use generic parenteral drugs for use in hospitals.

4. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004 on the control of concentrations between undertakings ([2]) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

5. The Commission invites interested third parties to submit their possible observations on the proposed concentration to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.12585 – BC PARTNERS / ACS DOBFAR / INFORLIFE

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').
([2]) OJ C 160, 5.5.2023, p. 1.

Observations can be sent to the Commission by email or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË